

January 29, 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
--	---

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Indegene Limited at its meeting held today, i.e., January 29, 2026, has:

1. Approved unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Auditors thereon for the quarter ended December 31, 2025.
The Financial Results along with the Limited Review Report of the Auditors with an unmodified opinion and CFO declaration are enclosed herewith.
2. Approved amendment to the Anti-Sexual Harassment Policy.
3. Approved allotment of shares under RSU 2020 Plan.
4. Approved re-constitution of Committees of the Board enclosed as Annexure I.

The meeting of the Board of Directors commenced at 5:30 P.M. IST and concluded at 6:07 P.M. IST.

The above information is being made available on the website of the Company <https://www.indegene.com/>.

This is for your information and records.

Yours Sincerely,

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer

Encl: A/a

Annexure I




Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040

- 
- i. **Nomination and Remuneration Committee:** Mr. Neeraj Bharadwaj, Non-Executive Independent Director, is inducted as a member of the Committee with effect from January 29, 2026. The Committee constitution is as follows:

Name	Designation	Position
Mr. Krishnamurthy Venugopala Tenneti	Non-Executive Independent Director	Chairperson
Mr. Pravin Udhyavara Bhadya Rao	Non-Executive Independent Director	Member
Mr. Jairaj Manohar Purandare	Non-Executive Independent Director	Member
Dr. Ashish Gupta	Non-Executive Independent Director	Member
Mr. Neeraj Bharadwaj	Non-Executive Independent Director	Member
Mr. Mark Francis Dzialga	Non-Executive Director	Member

- ii. **Investment Committee:** Mr. Neeraj Bharadwaj, Non-Executive Independent Director, is inducted as a member of the Committee with effect from January 29, 2026. The Committee constitution is as follows:

Name	Designation	Position
Mr. Krishnamurthy Venugopala Tenneti	Non-Executive Independent Director	Chairperson
Dr. Ashish Gupta	Non-Executive Independent Director	Member
Mr. Neeraj Bharadwaj	Non-Executive Independent Director	Member
Mr. Mark Francis Dzialga	Non-Executive Director	Member
Dr. Rajesh Bhaskaran Nair	Non-Executive Director	Member

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **INDEGENE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities as mentioned in Annexure I to this review report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial information of 1 subsidiary and 6 step down subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 179 million and Rs. 555 million for the quarter and nine months ended December 31, 2025 respectively, total profit after tax of Rs. 22 million and Rs. 34 million for the quarter and nine months ended December 31, 2025 respectively and total comprehensive income of Rs. 14 million and Rs. 23 million for the quarter and nine months ended December 31, 2025 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

Reporting on comparatives for all the reported periods in the Statement which were reviewed by the predecessor auditor

7. The consolidated financial results of the Company for the quarter and nine months ended December 31, 2024 and year ended March 31, 2025 included in the Statement, were reviewed/audited by the predecessor auditor who expressed an unmodified conclusion/opinion on those financial results on January 30, 2025 and April 28, 2025 respectively.

Our conclusion on the statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells**
Chartered Accountants
Firm's Registration No. 008072S



Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920JMFIEK5845

Place: Bengaluru
Date: January 29, 2026

Annexure I to Independent Auditor's Review Report on Review of Interim Consolidated Financial Results.

The Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025 include financial results of the following companies:

Sr. No.	Company Name	Category	Country of Incorporation
1	Indegene Limited	Holding Company	India
2	ILSL Holdings Inc.	Wholly Owned Subsidiary	USA
3	Indegene Inc.	Step Down Subsidiary	USA
4	Services Indegene Aptilon Inc.	Step Down Subsidiary	Canada
5	DT Associates Research and Consulting Services Ltd	Step Down Subsidiary	England
6	DT Associates Research and Consulting Inc.	Step Down Subsidiary	USA
7	Cult Health LLC	Step Down Subsidiary	USA
8	Indegene Japan Godo Kaisha, Japan	Step Down Subsidiary	Japan
9	Indegene Healthcare Mexico S DE RL DE CV	Wholly Owned Subsidiary	Mexico
10	Indegene Ireland Limited	Wholly Owned Subsidiary	Ireland
11	Indegene Healthcare Germany GmbH	Step Down Subsidiary	Germany
12	Indegene Fareast Pte Ltd	Step Down Subsidiary	Singapore
13	Indegene Europe LLC	Step Down Subsidiary	Switzerland
14	Indegene Lifesystems Consulting (Shanghai) Co. Ltd.	Step Down Subsidiary	China
15	Indegene Healthcare UK Limited	Step Down Subsidiary	England
16	Trilogy Writing & Consulting GmbH	Step Down Subsidiary	Germany
17	Trilogy Writing & Consulting Limited	Step Down Subsidiary	England
18	Trilogy Writing & Consulting Inc.	Step Down Subsidiary	USA
19	Trilogy Writing & Consulting Inc. (erstwhile Trilogy Writing and Consulting ULC (Canada) renamed w.e.f December 22, 2025)	Step Down Subsidiary	Canada
20	Indegene Spain S.L.U	Step Down Subsidiary	Spain
21	MJL Communications Group Ltd	Step Down Subsidiary	England
22	MJL Advertising Limited	Step Down Subsidiary	England
23	BioPharm Parent Holding, Inc	Step Down Subsidiary	USA
24	BioPharm Communications LLC	Step Down Subsidiary	USA
25	Addressable Health LLC	Step Down Subsidiary	USA
26	Warn and Co Limited	Step Down Subsidiary	England

INDEGENE LIMITED

CIN No. L73100KA1998PLC102040

Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2025

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	9,421	8,042	7,204	25,071	20,837	28,393
	(b) Other income (net)	194	197	377	612	816	1,072
	Total income	9,615	8,239	7,581	25,683	21,653	29,465
2	Expenses						
	(a) Employee benefits expense	5,680	5,158	4,438	15,653	13,301	18,152
	(b) Finance costs	46	38	32	121	189	220
	(c) Depreciation and amortisation expense	396	234	200	846	595	802
	(d) Other expenses	2,146	1,478	1,448	4,864	3,668	4,898
	Total expenses	8,268	6,908	6,118	21,484	17,753	24,072
3	Profit before tax (1-2)	1,347	1,331	1,463	4,199	3,900	5,393
4	Tax expense						
	- Current tax	874	379	338	1,537	1,053	1,491
	- Deferred tax	(556)	(69)	28	(552)	(44)	(165)
	Total tax expense	318	310	366	985	1,009	1,326
5	Profit for the period/year (3-4)	1,029	1,021	1,097	3,214	2,891	4,067
6	Other Comprehensive Income (OCI), net of taxes						
	<i>Items that will not be reclassified subsequently to the statement of profit or loss:</i>						
	Remeasurement of defined benefit obligation	6	24	11	42	18	(21)
	Income tax impact	(2)	(6)	(3)	(11)	(5)	5
	<i>Items that will be reclassified subsequently to profit or loss:</i>						
	Exchange differences on translating the financial statements of foreign operations	189	466	124	813	217	272
	Total Other Comprehensive Income for the period/year (net of tax)	193	484	132	844	230	256
7	Total comprehensive income for the period/year (5+6)	1,222	1,505	1,229	4,058	3,121	4,323
	Profit for the period/year attributable to:						
	Owners of the Parent	1,029	1,021	1,097	3,214	2,891	4,067
	Other Comprehensive Income for the period/year attributable to:						
	Owners of the Parent	193	484	132	844	230	256
	Total comprehensive income for the period/year attributable to Owners of the Parent	1,222	1,505	1,229	4,058	3,121	4,323
8	Paid-up equity share capital (Face value of ₹ 2 each)	480	480	478	480	478	479
9	Other equity						25,677
10	Earnings per equity share (face value of ₹ 2 each)*						
	(a) Basic (in ₹)	4.29	4.26	4.59	13.40	12.23	17.15
	(b) Diluted (in ₹)	4.26	4.23	4.55	13.32	12.12	17.02

*Earnings per share is not annualised for quarter and nine months ended.

See accompanying notes to the Consolidated Financial Results



INDEGENE LIMITED

CIN No. L73100KA1998PLC102040

Notes to the Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2025

(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Consolidated Financial Results of Indegene Limited ('the Company' or 'the Parent' or 'the Holding Company') together with its affiliates (collectively 'the Group'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "n" in the financial information denote amounts less than ₹ 0.50 million.
2. The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 January 2026 and approved by the Board of Directors at its meeting held on 29 January 2026. The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and nine months ended 31 December 2025 and have issued an unmodified review report on the same.
3. The Consolidated Financial Results for the quarter and nine months ended 31 December 2025, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
4. Acquisition of Biopharm Parent Holdings Inc.:
As on 30 September 2025, the Group had entered into a stock purchase agreement with BioPharm Parent Holding Inc., ('BioPharm') and Engage Acquisition Corp. ("Seller") to acquire 100% interest in BioPharm a specialized marketing services agency, part of Omnicom Health Group, for an aggregate purchase consideration of ₹ 9,146 (USD 104 million), including deferred and contingent earn out consideration. The Group believes that the acquisition will strengthen the Group's commercialization portfolio by integrating advanced AI and digital advertising technologies, enabling pharmaceutical companies to achieve more precise, scalable, and measurable marketing outcomes. Further on 01 October 2025, the Group had obtained control of BioPharm and has carried out the provisional purchase price allocation for the BioPharm acquisition during the quarter ended 31 December 2025 and the same will be finalised within the measurement period but in no event later than one year following the date of acquisition (01 October 2025).
5. Acquisition of Warn & Co Limited:
On 16 October 2025, the Group acquired 100% interest in Warn & Co Limited, a specialized transformation consulting firm, for an aggregate purchase consideration of ₹ 464 (GBP 3.91 million), including an earnout component. The acquisition has been accounted for as a business combination under Ind AS 103. The Group has carried out the provisional purchase price allocation for the Warn & Co Limited acquisition during the quarter ended 31 December 2025 and the same will be finalised within the measurement period but in no event later than one year following the date of acquisition (16 October 2025).
6. During the year 2020-21, the Group was named in a class action lawsuit filed in the U.S. District Court of New Jersey, alleging non-compliance with the Telephone Consumer Protection Act of 1991 ('TCPA') by sending unsolicited fax advertisements without the recipient's prior express invitation or permission.
In July 2025, the Court allowed the case to proceed as a class action. The Group's request to challenge this decision was not accepted. The matter remains ongoing and is progressing toward trial or potential settlement. Mediation discussions are expected in early 2026, with the Group participating on a no-admission-of-liability basis.
As of 31 December 2025, no settlement terms have been proposed or agreed, and the scope of potential claimants remains uncertain. Any financial obligation would depend on valid claims being filed and cannot be reliably estimated. Accordingly, no provision is considered necessary in the consolidated financial results at this stage.
7. On 10 November 2025, Indegene Ireland Limited, Company's wholly owned subsidiary has signed a Share Purchase Agreement ("SPA") to acquire 100% equity shares in CAKE Kommunikatiions Holding GmbH (an SPV created to hold 70% in Cake Kommunikatiions GmbH (AT), 100% in CAKE Kommunikatiions GmbH (DE) and 100% in CAKE Kommunikatiions AG (Switzerland)) and 30% in Cake Kommunikatiions GmbH (AT) from Werner Hinterberger [Collectively 'Cake Group'] for an amount not exceeding EUR 8.5 Million including earnout liability, subject to net working capital / net debt adjustments.

The acquisition is subject to meeting the closing conditions as defined in the SPA which are yet to be completed as on 31 December 2025.
8. On 31 December 2025, Indegene, Inc. and Trilogy Writing and Consulting GmbH, the step-down subsidiaries of the Company, signed a Share Purchase Agreement to acquire 100% equity shares of Trilogy Writing & Consulting Inc. (formerly Trilogy Writing and Consulting ULC), a wholly owned subsidiary of Trilogy Writing and Consulting GmbH, for a cash consideration of EURO 329,014. Subsequently, on 01 January 2026, the Company's step-down subsidiaries, Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc., both wholly owned by Indegene, Inc. USA, amalgamated to form Indegene Healthcare Canada Inc.
9. On 21 November 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group based on the evaluation of the Labour Code has concluded that these changes do not have any material impact on the Group's financial results. In case of any further clarification from the Government on other aspects of the New Labour Codes, the Group will evaluate and account for differential impact, if any, in subsequent periods on the consolidated financial results.



INDEGENE LIMITED

CIN No. L73100KA1998PLC102040

Notes to the Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2025

(All amounts in ₹ millions, except share data and where otherwise stated)

10 Segment information

Effective 01 October 2025, the Group has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the Chief operating decision maker reviews and evaluates performance of the business of the Group. Pursuant to the above, in accordance with the requirement specified in Ind AS 108, the comparative period information has been recasted to give the effect of this change.

Subsequent to the above change the Group will now have only 2 reportable segment i.e., Enterprise Commercial Solutions and Enterprise Medical Solutions.

Segment wise revenue and results are as follows:

Particulars	Quarter ended			Nine Months ended		Year ended
	31 December	30 September	31 December	31 December	31 December	31 March
	2025	2025	2024	2025	2024	2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment revenue						
Enterprise Medical Solutions	2,387	2,242	2,052	6,761	5,918	8,025
Enterprise Commercial Solutions	6,689	5,512	4,892	17,412	14,125	19,348
Others*	345	288	260	898	794	1,020
Total	9,421	8,042	7,204	25,071	20,837	28,393
2. Segment results						
Enterprise Medical Solutions	612	575	534	1,763	1,496	2,081
Enterprise Commercial Solutions	1,199	982	1,035	3,280	2,880	3,942
Others*	(55)	(59)	(62)	(164)	(229)	(329)
Total	1,756	1,498	1,507	4,879	4,147	5,694
Unallocable expenses	(161)	(92)	(189)	(325)	(279)	(351)
Depreciation and amortisation expense	(396)	(234)	(200)	(846)	(595)	(802)
Other income (net)	194	197	377	612	816	1,072
Finance cost	(46)	(38)	(32)	(121)	(189)	(220)
Tax expense	(318)	(310)	(366)	(985)	(1,009)	(1,326)
Profit after Tax	1,029	1,021	1,097	3,214	2,891	4,067

*Others mainly comprises of consultancy and clinical business.

Notes on Segment information

Operating segments are identified as components of an enterprise for which discrete financials information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Group's chief operating decision maker is the Chief Executive Officer and Executive Director.

Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

Bengaluru
29 January 2026



by Order of the Board of
INDEGENE LIMITED
Manish Gupta
Chief Executive Officer and Executive Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **INDEGENE LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Reporting on comparatives for all the reported periods in the Statement which were reviewed by the predecessor auditor

5. The standalone financial results of the Company for the quarter and nine months ended December 31, 2024 and year ended March 31, 2025 included in the Statement, were reviewed/audited by the predecessor auditors who expressed an unmodified conclusion/opinion on those financial results on January 30, 2025 and April 28, 2025 respectively.


Our conclusion on the Statement is not modified in respect of this matter.

For **Deloitte Haskins & Sells**
Chartered Accountants
Firm's Registration No. 008072S



Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920OYWFQL4466

Place: Bengaluru
Date: January 29, 2026




(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	2,901	3,067	2,867	8,524	8,269	10,936
	(b) Other income (net)	226	175	223	722	551	904
	Total income	3,127	3,242	3,090	9,246	8,820	11,840
2	Expenses						
	(a) Employee benefits expense	2,019	1,983	1,922	5,818	5,747	7,592
	(b) Finance costs	18	20	16	55	47	62
	(c) Depreciation and amortisation expense	95	86	65	254	193	262
	(d) Other expenses	505	378	426	1,256	1,113	1,539
	Total expenses	2,637	2,467	2,429	7,383	7,100	9,455
3	Profit before tax (1-2)	490	775	661	1,863	1,720	2,385
4	Tax expense						
	- Current tax	129	174	169	448	456	630
	- Deferred tax	13	2	(7)	17	(6)	(58)
	Total tax expense	142	176	162	465	450	572
5	Profit for the period/year (3-4)	348	599	499	1,398	1,270	1,813
6	Other Comprehensive Income (OCI), net of taxes						
	<i>Items that will not be reclassified subsequently to the statement of profit or loss:</i>						
	Remeasurement of defined benefit obligation	6	25	11	42	18	(21)
	Income tax impact	(1)	(7)	(3)	(11)	(5)	5
	<i>Items that will be reclassified subsequently to profit or loss:</i>						
	Exchange differences on translating the financial statements of foreign operations	-	-	^	-	(2)	3
	Total Other Comprehensive (Loss)/Income for the period/year (net of tax)	5	18	8	31	11	(13)
7	Total comprehensive income for the period/year (5+6)	353	617	507	1,429	1,281	1,800
8	Paid-up equity share capital (Face value of ₹ 2 each)	480	480	478	480	478	479
9	Other equity						18,403
10	Earning per equity share (face value ₹ 2 each)*						
	(a) Basic (in ₹)	1.45	2.50	2.09	5.83	5.38	7.64
	(b) Diluted (in ₹)	1.44	2.48	2.07	5.79	5.33	7.59

*Earnings per share is not annualised for quarter and nine months ended.

See accompanying notes to the Standalone Financial Results





Indegene Limited

CIN No. L73100KA1998PLC102040

Notes to the Statement of Standalone Financial Results for quarter and nine months ended 31 December 2025

(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Standalone Financial Results of the Indegene Limited ('the Company'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.
2. The above Standalone Financial Results have been reviewed by the Audit Committee meeting held on 28 January 2026 and approved by the Board of Directors at its meeting held on 29 January 2026. The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter and nine months ended 31 December 2025 and have issued an unmodified review report on the same.
3. The Standalone Financial Results for the quarter and nine months ended 31 December 2025, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
4. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results.
5. On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company based on the evaluation of the labour code has concluded that these changes do not have any material impact on the Company's Financial Results. In case of any further clarification from the Government on other aspects of the New Labour Codes, the Company will evaluate and account for differential impact, if any, in subsequent periods on the Standalone Financial Results.

By Order of the Board of
INDEGENE LIMITED



Manish Gupta

Chief Executive Officer and Executive Director

Bengaluru

29 January 2026

Date: January 29, 2026

The Declaration by CFO regarding audit report with unmodified opinion

I, Suhas Prabhu, Chief Financial Officer of the Company, hereby declare, that the Company's Statutory Auditors Deloitte Haskins & Sells, Chartered Accountants, Firm Registration No. 0080725 Chartered Accountants, have submitted an unmodified opinion / unqualified opinion on the unaudited Financial Results for the quarter ended December 31, 2025.

For Indegene Limited



Suhas Prabhu
Chief Financial Officer

indegene®

Registered office

Indegene Limited,
Third Floor, Aspen G-4 Block, Manyata Embassy Business
Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone : +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040